Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Backtracks On Cloning Patent For S. Korea Scientist

This article was originally published in PharmAsia News

Executive Summary

Australian authorities are taking a new look at the recent decision to grant a stem cell patent to a disgraced South Korean scientist. Hwang Woo-suk, who lost his job and faced court action after it was revealed he falsified parts of his breakthrough cloning research, was granted an Australia patent for that human embryo cloning technology. IP Australia, the country's intellectual property arm, said the government has delayed the effective date for the patent to become official. The agency would not comment on the delay other than to say it was "investigating the matter." (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel